Lakewood Amedex

What Lakewood Amedex does

Lakewood-Amedex Biotherapeutics, Inc. (Nasdaq: LABT) is a clinical-stage biopharmaceutical company developing a proprietary class of antimicrobials called Bisphosphocin® — small nucleotide derivatives that kill bacteria and fungi by depolarizing microbial cell membranes, producing rapid cell death (within minutes) and demonstrated activity against gram-positive, gram-negative, and drug-resistant pathogens including MRSA and VRE. The company's lead candidate, Nu-3, is a topically applied gel formulation of Bisphosphocin® currently in Phase 2 clinical development for the treatment of mildly to moderately infected diabetic foot ulcers (iDFU), an indication that affects roughly 40 million U.S. diabetics and an estimated 830 million patients worldwide, with 15–20% of cases caused by resistant pathogens.

The Bisphosphocin® platform underpins a broader pipeline targeting complicated urinary tract infections, pulmonary infections, and other indications via topical, catheter-instillation, and nebulizer delivery routes. The intellectual property estate comprises 72 granted patents and 29 pending applications across the US, Europe, China, India, Japan, Australia, and New Zealand, with composition-of-matter and formulation coverage extending through at least 2038 and up to 2044. Phase 2a (dosing-concentration study) is being conducted with Dr. David G. Armstrong (USC) as Study Chair and PERI as CRO; a Phase 2b protocol has been agreed with the FDA (NCT06020235).

The company is pre-revenue with no commercial product and a $3.10 million net loss for the nine months ended September 30, 2025 disclosed in its S-1. Its business model is a traditional prescription-pharmaceutical model: revenue is expected to be generated through post-approval sales to healthcare providers and hospital systems, with no current pricing, licensing, or royalty arrangements disclosed. Prior to its April 2026 direct listing on Nasdaq, the company planned a $7.5 million Series C Preferred private placement; it is led by CEO Kelvin Cooper, PhD, with Thomas Balzer, MD, PhD as CMO, Peter F. Ceccacci as CFO, and Doug Manion, M.D., FRCP(C) as Chairman.

Name

Lakewood Amedex

Legal name

Lakewood-Amedex Biotherapeutics, Inc.

Website

http://www.lakewoodamedex.com/

Company type

Public

Founded year

2006

Operating status

Ipo

Headcount range

11–50 employees

Short description

Lakewood-Amedex Biotherapeutics (Nasdaq: LABT) is a clinical-stage biopharmaceutical company developing the Bisphosphocin® class of novel antimicrobials, with lead candidate Nu-3, a topical gel for infected diabetic foot ulcers currently in Phase 2 trials.

Ownership category

akta.pro rank

Product category

Anti-infective Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

akta.pro secondary industry

Microbiome Modulating Small Molecules & Antibiotic Alternatives (HLAAAFAG)

Keywords

• Antimicrobial drug development
• Topical antimicrobial gel
• Diabetic foot ulcer treatment
• Clinical-stage biopharmaceuticals
• Antibiotic resistance therapeutics

Headquarters

HQ city

Sarasota

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Revenue: Pre-revenue clinical-stage company developing Bisphosphocin® class antimicrobials. Lead product Nu-3 is in Phase 2 development for infected diabetic foot ulcers. Revenue will be generated through prescription pharmaceutical sales following regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Lakewood Amedex is a clinical-stage biopharmaceutical company developing the proprietary Bisphosphocin® class of antimicrobials—small nucleotide derivatives that rapidly destabilize bacterial and fungal cell membranes. Its lead candidate, Nu-3, is a topical gel formulation currently in Phase 2 clinical trials for mildly-to-moderately infected diabetic foot ulcers (iDFU), with the broader Bisphosphocin® platform also targeting complicated urinary tract infections and pulmonary infections via multiple delivery modalities.

Product overview

Lakewood-Amedex Biotherapeutics is a clinical-stage biotech developing a novel class of antimicrobials called the Bisphosphocin® class. The company's primary product is Nu-3, a topical gel formulation for treating infected diabetic foot ulcers (iDFU), which is advancing through Phase 2 clinical trials. The Bisphosphocin® platform underlies Nu-3 and enables additional pipeline candidates targeting complicated urinary tract infections, pulmonary infections, and other indications via various delivery methods including topical gels, catheter instillation, and nebulizers.

Differentiator

Problem solved

Functional benefit

Products and services

• Nu-3 Nu-3 is a topical gel formulation of the Bisphosphocin® class being developed by Lakewood Amedex for the treatment of mildly-to-moderately infected diabetic foot ulcers (iDFU). The product is in Phase 2 clinical trials and demonstrates rapid bacterial killing through membrane destabilization with broad-spectrum activity against resistant strains including MRSA and VRE. It is intended for prescription use by wound care specialists, podiatrists, and infectious disease physicians treating diabetic patients with infected foot ulcers.
• Bisphosphocin® antimicrobial platform Bisphosphocin® is Lakewood Amedex's proprietary novel class of broad-spectrum antimicrobials consisting of small nucleotide derivatives that rapidly kill bacteria and fungi by depolarizing microbial cell membranes/walls, leading to cell death within minutes. The platform underpins Nu-3 and enables additional pipeline candidates targeting complicated urinary tract infections, pulmonary infections, and other indications through multiple delivery modalities including topical gels, catheter instillation, and nebulizers. The platform has demonstrated broad-spectrum activity against gram-positive, gram-negative, and drug-resistant pathogens including MRSA and VRE, with no susceptibility to resistance mechanisms in laboratory testing.

Quantifiable outcome

• Complete eradication of 105 E. coli bacteria within 10 minutes at 25 mg/ml concentration
• +2 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• Dr. David G. Armstrong (Keck School of Medicine of USC)coreStrategic or Co-development Partner · 25 June 2026Dr. David G. Armstrong, distinguished professor at the Keck School of Medicine of USC, appointed as Study Chair for Phase 2a clinical trial evaluating Nu-3 gel in patients with infected diabetic foot ulcers. He will also serve as Scientific Advisor to the company's iDFU program. Dr. Armstrong is recognized as a leading expert in diabetic foot care and limb preservation.
• Professional Education and Research Institute LLC (PERI)coreImplementation/ SI/ Consulting Partner · 12 May 2026PERI serves as the contract research organization for the Phase 2 clinical program of Nu-3. The Phase 2a study will compare 2%, 5%, and 10% gel concentrations to establish proof of concept, followed by Phase 2b evaluating different dosing regimens against placebo. PERI was selected for its track record in wound care and diabetic foot medicine. Trial began May 2026.
• Joseph Tucker, Ph.D. (Enveric Biosciences)coreOthers · 28 April 2026Joseph Tucker, Ph.D., CEO and director of Enveric Biosciences, appointed to Board of Directors following the company's direct listing on Nasdaq. Tucker brings over two decades of public and private company leadership, capital markets expertise, and drug development experience with more than $100 million in capital raised throughout his career. Appointment intended to support advancement of Nu-3 through Phase 2 clinical trials.
• Tiberend Strategic Advisors, Inc.coreGTM or Marketing PartnerInvestor Relations contact: David Irish, 231-632-0002, [email protected]. Media Relations: Casey McDonald, 646-577-8520, [email protected]. Tiberend serves as the company's investor relations and media relations advisor for shareholder communications and media inquiries.

Scale indicators10 records

Recent moves8 records

Expansion highlights5 records

Market position

Competitive moat4 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/lakewood-amedex-inc.

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lakewood Amedex